Bispecific Antibody Market Size, Share, Growth, Trends, and Global Industry Analysis: By Drug Type (Blinatumomab, Catumaxomab, Duligotumab, Others), By Indication (Cancer, Infectious Disease, Inflammatory & Autoimmune Disorders, CNS Disorders, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and Region

Bispecific Antibody Market was valued at US$ 1,715.9 million in 2023 and is poised to grow at a CAGR of 11.3% from 2024 to 2030. Bispecific antibodies are antibodies that are engineered in a way that it binds at two binding sites directed at two different antigens or two different epitopes on the same antigen. The bispecific antibodies have therapeutic effects superior to that of monoclonal antibodies with a broad application for tumor immunotherapy and treatment for other diseases.  The bispecific antibodies are evolving as the most commonly used and accurate method in the treatment of various types of cancer such as, lung cancer, prostate cancer, breast cancer, and colon. The increasing prevalence of cancer is expected to drive the market growth. For instance, according to the World Health Organization, about 18 million people deaths were registered due to cancer.

In addition, the development of new and innovative technologies, such as the use of antibody engineering and hybridoma technology is expected to propel the growth. Furthermore, bispecific antibodies have greater specificity and affinity towards target cells leading to greater efficacy in treatment outcome and is expected to further fuel the growth over the forecast period. However, high cost of bispecific antibodies along with regulatory challenges in conducting clinical trials is expected to hinder the growth the market over the forecast period. Whereas factors like increasing demand for personalized medicines, growing application of bispecific antibodies in treatment of other diseases such as autoimmune disorder, infectious disease, and ophthalmology is expected to open up significant opportunities for the market players in the forecast period. Furthermore, ongoing clinical trials for the novel bispecific antibodies by pharmaceutical companies are expected to aid the growth. 

Key Developments

• In January 2023, the FDA approved Genentech’s bispecific antibody Glofitamab, CD20- and CD3-binding monoclonal antibody for the treatment of relapsed or refractory large B cell lymphoma.
• In May 2023, AbbVie received the FDA approval for EPKINLY (epcoritamab-bysp) for the treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in adults.